A

AbbVie

Global biopharmaceutical company developing medicines

Early-Stage Biologics Data Scientist - Early Stage PDST CMC

Full-TimeUpdated on 10/23/2026
$109.5k - $208.5k/yr+ Long-term incentive program
Senior
Bachelor's, Master's, PhD
North Chicago, IL, USA
Hybrid
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A bachelor's degree in computer science or a related discipline with 7 years of experience, a master's degree with 6 years of experience, or a PhD with 2 years of experience in IT or application program development.
  • Hands-on experience building and deploying data science or machine learning solutions in a scientific or engineering-intensive environment.
  • Expert-level Python proficiency and deep familiarity with the scientific Python ecosystem, including NumPy, pandas, scikit-learn, PyTorch or TensorFlow, and modern data engineering such as cloud, big data, and pipeline orchestration.
  • A strong foundation in business analytics and mastery of tools such as R, Dataiku, AWS SageMaker, Spark, and Tableau.
  • Experience with design of experiments (DoE) methodologies, Bayesian methods, or active learning in scientific applications.
  • Familiarity with knowledge graph, retrieval-augmented, or orchestrated AI/LLM-based systems applied to scientific or technical domains.
  • Experience applying data science in a GxP-regulated environment, with working knowledge of FDA/EMA expectations for process validation, continued process verification (CPV), and control strategy.
  • Familiarity with MLOps principles, model lifecycle management, or deployment of analytical tools in regulated or enterprise environments.
  • Ability to define a problem space, drive solutions to completion, and take accountability for outcomes.
  • Ability to evaluate the landscape of available approaches and select tools based on fit-for-purpose reasoning.
  • Ability to build models that can be explained, defended, and improved, and to apply the same standard to others’ work.
  • Ability to earn the confidence of scientists, engineers, and quality professionals through accurate, clear, and useful contributions.
  • Ability to work effectively on high-stakes analytical problems amid ambiguity.
Responsibilities
  • Develop, validate, and deploy predictive models that support early-stage biologics process development decisions, including upstream bioprocess performance, downstream purification behavior, and critical quality attribute (CQA) outcomes.
  • Design and apply hybrid modeling approaches that combine first-principles process understanding with data-driven techniques while maintaining scientific interpretability.
  • Build and evolve analytical frameworks supporting digital twin concepts and in-silico process optimization to enable more effective experimental strategies and accelerated development timelines.
  • Partner with process scientists, analytical scientists, and engineers to define data strategies for new programs, including which data to collect, how to structure it, and how to connect it across experimental campaigns.
  • Identify and address data quality, integration, and accessibility challenges in existing datasets, and advocate for and help implement improved data infrastructure within the pod.
  • Ensure models, analyses, and data assets align with GxP principles and regulatory expectations, with appropriate documentation and traceability.
  • Select suitable approaches for analytical and AI-driven workflows, including classical statistical methods, supervised or unsupervised machine learning, retrieval-augmented generation, orchestrated AI pipelines, and hybrid mechanisms, based on scientific need, data availability, and interpretability requirements.
  • Identify opportunities to automate, accelerate, or augment scientific workflows using intelligent tooling, and own the scoping, building, and validation of those solutions.
  • Stay current with AI and machine learning methods and evaluate emerging approaches for applicability to biologics development.
  • Collaborate with process development scientists to design statistically rigorous, resource-efficient, and informative experiments using design of experiments (DoE), Bayesian optimization, and active learning strategies.
  • Support process characterization studies with statistical analysis, model-based risk assessment, and data-driven identification of critical process parameters (CPPs) and their relationships to critical quality attributes (CQAs).
  • Contribute to technology transfer readiness by developing analytical frameworks that translate process understanding into transferable, defensible process knowledge.
  • Translate complex quantitative analyses into actionable insights for scientists, engineers, and senior leaders, connecting technical detail with business relevance.
  • Participate in cross-functional discussions and contribute data-driven perspectives to program decisions, risk assessments, and development strategies.
  • Document, present, and defend analytical work for internal technical reviews and regulatory submissions.
Desired Qualifications
  • An advanced degree (M.S. or Ph.D.) in Data Science, Biostatistics, Chemical or Biochemical Engineering, Computational Biology, or a closely related quantitative discipline.
  • Five or more years of hands-on experience building and deploying data science or machine learning solutions in a scientific or engineering-intensive environment.
  • Experience working with data from laboratory and manufacturing systems such as LIMS, MES, DeltaV/historian, and eBR platforms, and building scalable data pipelines for process analytics.
  • Direct experience in biologics or bioprocess development, such as cell culture, fermentation, chromatography, filtration, or formulation, in an industrial or academic research setting.
  • Familiarity with CMC development concepts, including process characterization, scale-up, technology transfer, or regulatory filing support (BLA/IND).
  • Familiarity with biopharmaceutical data types, including bioreactor process data, chromatography profiles, analytical assay results, and spectroscopic measurements.
  • Familiarity with technology transfer workflows, process characterization study design, or commercial process validation (PPQ/PV) in a biologics or pharmaceutical context.
  • A track record of scientific communication through publications, regulatory submissions, technical reports, or equivalent work demonstrating the ability to convey complex analytical work clearly and credibly.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.

Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.